Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
Reprint PDF

Keywords

bio therapeutic
comparability
Critical Quality Attributes
Developing countries
generics
health policies
high quality biosimilars
regulation

How to Cite

1.
Mendoza-Macedo K, Romero-Díaz AJ, Miranda-Hernández MP, Campos-García VR, Ramírez-Ibañez ND, Juárez-Bayardo LC, Moreno-Duran K, Cedillo-Robles MS, Pérez NO, Jung-Cook H, Flores-Ortiz LF, Medina-Rivero E. Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America. Electron. J. Biotechnol. [Internet]. 2016 Nov. 15 [cited 2024 Nov. 2];24. Available from: https://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/2016.10.003

Abstract

Background: Developing countries have an estimate of ten times more approved biosimilars than developed countries. This disparity demands the need of an objective regulation that incorporates health policies according to the technological and economical capabilities of each country. One of the challenges lies on the establishment of comparability principles based on a physicochemical and biological characterization that should determine the extent of additional non-clinical and clinical studies. This is particularly relevant for licensed biosimilars in developing countries, which have an extensive clinical experience since their approval as generics, in some cases more than a decade. To exemplify the current status of biosimilars in Mexico, a characterization exercise was conducted on licensed filgrastim biosimilars using pharmacopeial and extended characterization methodologies.

Results: Most of the evaluated products complied with the pharmacopeial criteria and showed comparability in their Critical Quality Attributes (CQAs) towards the reference product. These results were expected in accordance with their equivalent performance during their licensing as generics. Accordingly, a rational approval and registration renewal scheme for biosimilars is proposed, that considers the proper identification of CQAs and its thoroughly evaluation using selected techniques.

Conclusions: This approach provides support to diminish uncertainty of exhibiting different pharmacological profiles and narrows or even avoids the necessity of comparative clinical studies. Ultimately, this proposal is intended to improve the accessibility to high quality biosimilars in Latin America and other developing countries.

Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.